Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 08, 2025.

Emphasis Of MatterPat Growth 25pctExceptional ItemResults View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹482.40

prior close

₹485.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%-0.8% vs market

Pharmaceuticals peers, median of 148sector+0.3%-1.0% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+2.6

15m

+2.4

30m

+1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.2-0.8+0.3-1.0

Next day

-0.4+0.2-0.6+0.3-0.7

+1.3+0.9+0.4+0.6+0.6

-2.2+0.1-2.2-0.3-1.8

-1.6+1.6-3.2+0.5-2.2

-0.6+2.8-3.4+0.6-1.1

-0.2+3.0-3.3+0.8-1.0

15d

-1.1+2.8-3.9+0.1-1.3

-4.6+3.1-7.7+1.5-6.1

-3.6+1.4-5.1-1.5-2.1

-9.2+1.4-10.6-4.2-5.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Akums Drugs and Pharmaceuticals' board approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, revenue from operations was ₹3,304.43 million (vs ₹3,172.75 million in Q1 FY25, up ~4% YoY), profit before tax rose to ₹595.06 million (vs ₹370.55 million), and profit after tax jumped to ₹448.67 million (vs ₹275.89 million, up ~63% YoY), translating to an EPS of ₹2.93. On a consolidated basis, revenue from operations was ₹10,240.32 million (vs ₹10,191.13 million in Q1 FY25, broadly flat), PBT was ₹956.46 million (vs ₹874.78 million), and PAT was ₹646.85 million (vs ₹612.08 million, up ~5.7% YoY) with EPS of ₹4.15. The statutory auditor's limited review report is clean (unqualified) but includes an emphasis-of-matter note regarding the Income Tax Department's search and seizure operations carried out in January 2025, whose outcome and financial impact remain unascertainable. The board also re-appointed Vibhor Gupta & Associates as internal auditor for FY 2025-26, re-constituted the Audit, Stakeholders Relationship, and Risk Management committees, and designated Rajkumar Bafna (President – Finance) and Tarun Kapoor (Sr. VP – IT) as Senior Management Personnel. The company confirmed that all ₹6,373.70 million of net IPO proceeds have been fully utilised as per the stated objects, with no deviation.

Likely market impact

Strong standalone earnings growth (PAT up ~63% YoY) signals margin expansion and is broadly positive for shareholders, though consolidated growth was muted. The unresolved Income Tax search from January 2025 remains a key overhang – investors should monitor any future demand or order from the IT Department, as any adverse outcome could materially impact financials. Committee changes and internal auditor re-appointment are routine governance actions.